Home › Compare › DVAX vs BTI

DVAX vs BTI: Dividend Comparison 2026

DVAX yields 12.90% · BTI yields 5.38%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 DVAX wins by $9.1K in total portfolio value
10 years
DVAX
DVAX
● Live price
12.90%
Share price
$15.50
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$46.8K
Annual income
$2,879.44
Full DVAX calculator →
BTI
BTI
● Live price
5.38%
Share price
$58.47
Annual div
$3.15
5Y div CAGR
11.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$37.7K
Annual income
$2,786.64
Full BTI calculator →

Portfolio growth — DVAX vs BTI

📍 DVAX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodDVAXBTI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, DVAX + BTI cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
DVAX pays
BTI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

DVAX
Annual income on $10K today (after 15% tax)
$1,096.77/yr
After 10yr DRIP, annual income (after tax)
$2,447.52/yr
BTI
Annual income on $10K today (after 15% tax)
$457.40/yr
After 10yr DRIP, annual income (after tax)
$2,368.64/yr
At 15% tax rate, DVAX beats the other by $78.88/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of DVAX + BTI for your $10,000?

DVAX: 50%BTI: 50%
100% BTI50/50100% DVAX
Portfolio after 10yr
$42.2K
Annual income
$2,833.04/yr
Blended yield
6.71%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BTI right now

DVAX
Analyst Ratings
9
Buy
1
Hold
1
Sell
Consensus: Buy
Price Target
$27.00
+74.2% upside vs current
Range: $20.00 — $32.00
Altman Z
2.4
Piotroski
6/9
BTI
Analyst Ratings
12
Buy
4
Hold
2
Sell
Consensus: Buy
Price Target
$40.00
-31.6% upside vs current
Range: $40.00 — $40.00
Altman Z
2.1
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

DVAX buys
0
BTI buys
0
No recent congressional trades found for DVAX or BTI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricDVAXBTI
Forward yield12.90% ✓5.38%
Annual dividend / share$2.00$3.15 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%11.3% ✓
Portfolio after 10y$46.8K ✓$37.7K
Annual income after 10y$2,879.44 ✓$2,786.64
Total dividends collected$20.6K ✓$14.3K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyBuy
Analyst price target$27.00$40.00 ✓

Year-by-year: DVAX vs BTI ($10,000, DRIP)

YearDVAX PortfolioDVAX Income/yrBTI PortfolioBTI Income/yrGap
1← crossover$11,990$1,290.32$11,299$598.92+$691.00 → DVAX
2$14,276$1,445.92$12,794$703.91+$1.5K → DVAX
3$16,884$1,608.88$14,518$829.07+$2.4K → DVAX
4$19,844$1,778.34$16,513$978.64+$3.3K → DVAX
5$23,186$1,953.40$18,827$1,157.84+$4.4K → DVAX
6$26,943$2,133.11$21,518$1,373.12+$5.4K → DVAX
7$31,145$2,316.51$24,657$1,632.46+$6.5K → DVAX
8$35,828$2,502.66$28,329$1,945.74+$7.5K → DVAX
9$41,026$2,690.60$32,637$2,325.33+$8.4K → DVAX
10$46,778$2,879.44$37,708$2,786.64+$9.1K → DVAX

DVAX vs BTI: Complete Analysis 2026

DVAX — Stock

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.

Full DVAX Calculator →

BTI — Consumer Staples

British American Tobacco p.l.c. provides tobacco and nicotine products to consumers in the Americas, Europe, the Asia-Pacific, the Middle East, Africa, and the United States. It offers vapour, heated, and modern oral nicotine products; combustible cigarettes; and traditional oral products, such as snus and moist snuff. The company provides its products under the Vuse, glo, Velo, Grizzly, Kodiak, Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Newport, Natural American Spirit, and Camel brands. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is based in London, the United Kingdom.

Full BTI Calculator →
📬

Get this DVAX vs BTI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

DVAX vs SCHDDVAX vs JEPIDVAX vs ODVAX vs KODVAX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.